Enliven Therapeutics, Inc.

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end BURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Kristine Ball to its Board of Directors, effective immediately.

Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).

Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $43.20 and last traded at $43.4350. 62,397 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,251,624 shares. The stock had previously

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.